Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Vet Res ; 43: 51, 2012 Jun 11.
Artigo em Inglês | MEDLINE | ID: mdl-22686373

RESUMO

Protection of cattle from alcelaphine herpesvirus-1 (AlHV-1)-induced malignant catarrhal fever (MCF) has been described previously, using an attenuated virus vaccine in an unlicensed adjuvant. The vaccine was hypothesised to induce a protective barrier of virus-neutralising antibody in the oro-nasal region, supported by the observation of high titre neutralising antibodies in nasal secretions of protected animals. Here we describe further analysis of this vaccine strategy, studying the effectiveness of the vaccine formulated with a licensed adjuvant; the duration of immunity induced; and the virus-specific antibody responses in plasma and nasal secretions. The results presented here show that the attenuated AlHV-1 vaccine in a licensed adjuvant protected cattle from fatal intranasal challenge with pathogenic AlHV-1 at three or six months. In addition, animals protected from MCF had significantly higher initial anti-viral antibody titres than animals that succumbed to disease; and these antibody titres remained relatively stable after challenge, while titres in vaccinated animals with MCF increased significantly prior to the onset of clinical disease. These data support the view that a mucosal barrier of neutralising antibody blocks infection of vaccinated animals and suggests that the magnitude of the initial response may correlate with long-term protection. Interestingly, the high titre virus-neutralising antibody responses seen in animals that succumbed to MCF after vaccination were not protective.


Assuntos
Doenças dos Bovinos/imunologia , Gammaherpesvirinae/imunologia , Infecções por Herpesviridae/veterinária , Febre Catarral Maligna/imunologia , Vacinas Virais/imunologia , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/farmacologia , Animais , Anticorpos Antivirais/análise , Anticorpos Antivirais/sangue , Antígenos Virais/análise , Bovinos , Doenças dos Bovinos/virologia , Ensaio de Imunoadsorção Enzimática/veterinária , Gammaherpesvirinae/fisiologia , Infecções por Herpesviridae/imunologia , Infecções por Herpesviridae/virologia , Imunidade Ativa/efeitos dos fármacos , Masculino , Febre Catarral Maligna/virologia , Testes de Neutralização/veterinária , Nariz/virologia , Fatores de Tempo , Vacinas Atenuadas/administração & dosagem , Vacinas Atenuadas/imunologia , Vacinas Virais/administração & dosagem
2.
Vet Immunol Immunopathol ; 151(3-4): 303-14, 2013 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-23273932

RESUMO

Bovine neonatal pancytopenia (BNP) is a recently described haemorrhagic disease of calves characterised by thrombocytopenia, leucopenia and bone marrow depletion. Feeding colostrum from cows that have previously produced a BNP affected calf has been shown to induce the disease in some calves, leading to the hypothesis that alloantibodies in colostrum from dams of affected calves mediate destruction of blood and bone marrow cells in the recipient calves. The aims of the current experimental study were first to confirm the role of colostrum-derived antibody in mediating the disease and second to investigate the haematopoietic cell lineages and maturation stages depleted by the causative antibodies. Clinical, haematological and pathological changes were examined in 5 calves given a standardised pool of colostrum from known BNP dams, and 5 control calves given an equivalent pool of colostrum from non-BNP dams. All calves fed challenge colostrum showed progressive depletion of bone marrow haematopoietic cells and haematological changes consistent with the development of BNP. Administration of a standardised dose of the same colostrum pool to each calf resulted in a consistent response within the groups, allowing detailed interpretation of the cellular changes not previously described. Analyses of blood and serial bone marrow changes revealed evidence of differential effects on different blood cell lineages. Peripheral blood cell depletion was confined to leucocytes and platelets, while bone marrow damage occurred to the primitive precursors and lineage committed cells of the thrombocyte, lymphocyte and monocyte lineages, but only to the more primitive precursors in the neutrophil, erythrocyte and eosinophil lineages. Such differences between lineages may reflect cell type-dependent differences in levels of expression or conformational nature of the target antigens.


Assuntos
Doenças dos Bovinos/imunologia , Colostro/imunologia , Isoanticorpos/administração & dosagem , Isoanticorpos/efeitos adversos , Pancitopenia/veterinária , Animais , Animais Recém-Nascidos , Células Sanguíneas/imunologia , Células Sanguíneas/patologia , Medula Óssea/imunologia , Medula Óssea/patologia , Bovinos , Doenças dos Bovinos/sangue , Doenças dos Bovinos/patologia , Linhagem da Célula/imunologia , Feminino , Genes MHC da Classe II , Células-Tronco Hematopoéticas/imunologia , Células-Tronco Hematopoéticas/patologia , Modelos Imunológicos , Pancitopenia/imunologia , Pancitopenia/patologia , Gravidez
3.
BMC Res Notes ; 5: 599, 2012 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-23110710

RESUMO

BACKGROUND: Bovine neonatal pancytopenia (BNP) is a syndrome characterised by thrombocytopenia associated with marked bone marrow destruction in calves, widely reported since 2007 in several European countries and since 2011 in New Zealand. The disease is epidemiologically associated with the use of an inactivated bovine virus diarrhoea (BVD) vaccine and is currently considered to be caused by absorption of colostral antibody produced by some vaccinated cows ("BNP dams"). Alloantibodies capable of binding to the leukocyte surface have been detected in BNP dams and antibodies recognising bovine MHC class I and ß-2-microglobulin have been detected in vaccinated cattle. In this study, calves were challenged with pooled colostrum collected from BNP dams or from non-BNP dams and their bone marrow hematopoietic progenitor cells (HPC) cultured in vitro from sternal biopsies taken at 24 hours and 6 days post-challenge. RESULTS: Clonogenic assay demonstrated that CFU-GEMM (colony forming unit-granulocyte/erythroid/macrophage/megakaryocyte; pluripotential progenitor cell) colony development was compromised from HPCs harvested as early as 24 hour post-challenge. By 6 days post challenge, HPCs harvested from challenged calves failed to develop CFU-E (erythroid) colonies and the development of both CFU-GEMM and CFU-GM (granulocyte/macrophage) was markedly reduced. CONCLUSION: This study suggests that the bone marrow pathology and clinical signs associated with BNP are related to an insult which compromises the pluripotential progenitor cell within the first 24 hours of life but that this does not initially include all cell types.


Assuntos
Células-Tronco Hematopoéticas/patologia , Pancitopenia/patologia , Células-Tronco Pluripotentes/patologia , Trombocitopenia/patologia , Animais , Animais Recém-Nascidos , Biomarcadores/metabolismo , Biópsia , Bovinos , Proliferação de Células , Forma Celular , Células Cultivadas , Ensaio de Unidades Formadoras de Colônias , Colostro/imunologia , Vírus da Diarreia Viral Bovina/imunologia , Feminino , Células-Tronco Hematopoéticas/imunologia , Células-Tronco Hematopoéticas/metabolismo , Masculino , Pancitopenia/imunologia , Pancitopenia/metabolismo , Projetos Piloto , Células-Tronco Pluripotentes/imunologia , Células-Tronco Pluripotentes/metabolismo , Gravidez , Síndrome , Trombocitopenia/imunologia , Trombocitopenia/metabolismo , Fatores de Tempo , Vacinação , Vacinas/imunologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa